Aging, Healthy, Vascular Stiffness
Conditions
Keywords
ivabradine, heart rate, aging, visco-elasticity
Brief summary
The conduit arteries exhibit a viscoelastic behavior. Visco-elasticity is partially regulated by endothelium and contributes to the optimization of the heart-vessel coupling. Aging or high resting heart rate (HR) could alter visco-elastic properties leading to increase stiffness of the conduit arteries, an independent cardiovascular risk factor, and degradation of heart-vessel coupling. Lowering HR with ivabradine could reduce these effects. The objective of this study is to assess the effect of HR reduction by repeated administration of ivabradine on visco-elastic properties, vascular geometry and function of common carotid artery, and on cardiovascular hemodynamic in healthy subject. The influence of aging on ivabradine effects are studied too. 30 healthy volunteers aged between 25 and 65 years old, with a HR ≥ 70 bpm, will receive ivabradine or placebo during 8 days in a single center, randomized, cross-group, double blinded, placebo-controlled study. Each period of treatment will be separate by 12 to 16 days of wash-out. Each subject will participate in an exploration visit, including evaluation of visco-elastic properties, vascular geometry and function of common carotid artery, and cardiovascular hemodynamic, before and after ivabradine or placebo taking.
Interventions
DRUGivabradine
It is a cross over study with two arms : either ivabradine-placebo or placebo-ivabradine. The capsules containing the placebo or ivabradine are completely identical.
DRUGlactose capsule (placebo)
It is a cross over study with two arms : either ivabradine-placebo or placebo-ivabradine. The capsules containing the placebo or ivabradine are completely identical.
Sponsors
University Hospital, Rouen
Institut National de la Santé Et de la Recherche Médicale, France
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
25 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
* Healthy volunteers * Caucasian * Resting heart rate ≥70 bpm (mean of 3 measures after 15 minutes of rest) * No significant EKG abnormality * No significant biological abnormalities at inclusion * Healthy volunteers able to read and understand information letter and to give written informed consent * Healthy volunteers with medical insurance * Contraception for two months for women of childbearing age (Estrogen contraceptive or intrauterine device or tubal ligation) (NB : women with amenorrhea for more than 2 years will be considered postmenopausal)
Exclusion criteria
* Subjects who don't understand french language * Person deprived of liberty by an administrative or judicial decision or protected adult subject (under guardianship) * Pregnant women, nursing mother or women without contraception * Healthy volunteers who participate to an other trial / participated to an other trial without drugs during the last month or a trial with drugs during the last 3 months * Hypersensitivity to the active substance or to any of the excipients * Congenital galactosemia, lactase deficiency, or glucose-galactose malabsorption * Body mass index (BMI) \< 18 kg/m² or \> 30 kg/m² * Severe hypotension (\< 90/50 mmHg) (3 measures after 15 minutes of rest) * Essential or secondary Hypertension (SBP ≥140 mmHg and/or DBP ≥90 mmHg) (3 measures after 15 minutes of rest) * Active smoking at the day of inclusion (\>5 cigarettes/day) * Severe hypercholesterolemia (Total cholesterol \>2,5 g/L) * Practice sports intensively (≥ 1 hour/day) * Renal insufficiency (creatinine clearance ≤ 60 ml/min/1,73 m² Cockroft and Gault formula) * Known liver failure * Known heart failure or suspected heart failure (congestive episode) * Atrial fibrillation * High-grade conduction block (Sick sinus syndrome, sino-atrial block or grade 2 or 3 atrio-ventricular block) * Abnormal corrected QT with Bazett formula (cQT \> 450 ms (men) or \> 470 ms (women)). * Pacemaker * All cardiac or extra cardiac diseases, active or with sequelae, which, in the opinion of the investigator, is accompanied by a risk of cardiac or vascular consequences * Retinal disease * Taking any medication is prohibited during the study except oral contraceptive, acetaminophene or decision of the investigator. In addition, the administration of drugs listed in schedule 2 during the previous 4 weeks prohibits inclusion.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change from baseline in viscosity of the common carotid artery | 8 days after first administration of ivabradine or placebo |
Secondary
| Measure | Time frame |
|---|---|
| Change from baseline in diameter of the common carotid artery | 8 days after first administration of ivabradine or placebo |
| Change from baseline in intima-media thickness of the common carotid artery | 8 days after first administration of ivabradine or placebo |
| Change from baseline in carotid distensibility | 8 days after first administration of ivabradine or placebo |
| Change from baseline in carotid-femoral pulse wave velocity | 8 days after first administration of ivabradine or placebo |
| Change from baseline in plasma levels of biomarkers of endothelial function | 8 days after first administration of ivabradine or placebo |
| Change from baseline in peripheral and central pressures | 8 days after first administration of ivabradine or placebo |
| Change from baseline in Buckberg index | 8 days after first administration of ivabradine or placebo |
| Change from baseline in cardiac output | 8 days after first administration of ivabradine or placebo |
Countries
France
Contacts
PRINCIPAL_INVESTIGATORFrederic Roca, MD
University Hospital, Rouen
STUDY_CHAIRRobinson Joannides, MD,PhD
University Hospital, Rouen
Outcome results
None listed